DISCLAIMER: This page is intended for members of the general public in Greece only.
The information provided on this site is intended for general information and education for Greece-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Greece.
National Medicines Agency
Mediterranean 284
GR-15562 Cholargos, Athens
Tel: +30 21 32040380/337
Fax: +30 21 06549585
Website: www.eof.gr
Contact Us
Tel: +30 21 1198 3631
09:00 - 17:00
Monday - Friday